Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target Raised to $28.00

Centessa Pharmaceuticals (NASDAQ:CNTA) had its target price increased by Guggenheim from $24.00 to $28.00 in a research report released on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other brokerages have also issued reports on CNTA. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $11.00 to $26.00 in a report on Thursday, September 19th. Jefferies Financial Group increased their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. B. Riley started coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 target price on the stock. Finally, BMO Capital Markets raised their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Stock Performance

CNTA stock opened at $16.00 on Friday. Centessa Pharmaceuticals has a one year low of $5.58 and a one year high of $18.74. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -10.46 and a beta of 1.47. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.29 and a current ratio of 21.52. The firm has a 50-day simple moving average of $15.90 and a two-hundred day simple moving average of $12.16.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. On average, equities analysts forecast that Centessa Pharmaceuticals will post -1.62 EPS for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 12,198 shares of the company’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total value of $148,449.66. Following the sale, the insider now owns 241,171 shares in the company, valued at $2,935,051.07. This represents a 4.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Saurabh Saha sold 2,592 shares of the firm’s stock in a transaction that occurred on Wednesday, October 23rd. The stock was sold at an average price of $15.32, for a total transaction of $39,709.44. Following the sale, the chief executive officer now directly owns 630,661 shares in the company, valued at $9,661,726.52. The trade was a 0.41 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 325,031 shares of company stock worth $5,213,043. Company insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in CNTA. Acadian Asset Management LLC acquired a new position in shares of Centessa Pharmaceuticals in the first quarter worth about $330,000. Platinum Investment Management Ltd. raised its holdings in Centessa Pharmaceuticals by 27.3% in the 1st quarter. Platinum Investment Management Ltd. now owns 485,174 shares of the company’s stock worth $5,482,000 after purchasing an additional 104,091 shares during the period. EntryPoint Capital LLC purchased a new position in Centessa Pharmaceuticals during the first quarter worth approximately $109,000. Affinity Asset Advisors LLC grew its holdings in Centessa Pharmaceuticals by 4.4% in the first quarter. Affinity Asset Advisors LLC now owns 830,546 shares of the company’s stock valued at $9,385,000 after purchasing an additional 34,817 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Centessa Pharmaceuticals by 16.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock valued at $33,427,000 after purchasing an additional 418,615 shares during the period. 82.01% of the stock is owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.